VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing product candidates for patients with depression, other diseases and disorders related to the central nervous system (CNS), and cancer. It uses stem cell technology platform for drug rescue, to identify and develop new chemical entities (NCEs) for its internal drug candidate pipeline. The Company's products include CardioSafe 3D, LiverSafe 3D and AV-101 (L-4-cholorkyurenine). Its CardioSafe 3D bioassay system uses human pluripotent stem cell (hPSC)-derived cardiomyocytes. Its LiverSafe 3D bioassay system uses hPSC-derived hepatocytes (liver cells), to predict potential liver toxicity of NCEs, including potential drug metabolism issues and adverse drug-drug interactions. AV-101 is a small molecule prodrug for major depressive disorder (MDD). Its VSTA-heps has functionally in various problems related to commercially-available (cadaver) hepatocytes.